ShareThis Page

Newsmaker: Dr. Anette Duensing

| Friday, Sept. 7, 2012, 12:02 a.m.
Anette Duensing, 43, M.D. recently received funding from the GIST Cancer Research Fund — a patient-driven organization that funds research on gastrointestinal stromal tumors, or GISTs. This is the seventh year in a row that the research fund supports research in Duensing’s laboratory.

Dr. Anette Duensing

Noteworthy: Duensing received funding from the GIST Cancer Research Fund — a patient-driven organization that funds research on gastrointestinal stromal tumors, or GISTs. This is the seventh consecutive year that the fund has supported research in Duensing's laboratory.

Age: 43

Residence: O'Hara

Family: Husband, Stefan

Occupation: Assistant professor of pathology, University of Pittsburgh School of Medicine

Background: In 2000, during her postdoctoral fellowship at Brigham and Women's Hospital in Boston, Duensing experienced firsthand the tumor remission of the first GIST patient treated with the therapy drug Gleevec. Since then, her research has focused on a better molecular understanding of the biology of GISTs and the mode of action of Gleevec. Duensing joined the University of Pittsburgh Cancer Institute in 2003.

Education: Medical degree from the University of Hannover Medical School, Hannover, Germany, in 1997

Quote: “This generous funding has allowed us to significantly expand our efforts identifying novel treatment options for GIST patients — in particular for patients whose tumors have become resistant to Gleevec over time.”

— Chris Togneri

TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.